Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

Philippe MoreauHematology Department, University Hospital Hôtel-Dieu, Nantes, France; Correspondence[email protected]

Katja C. WeiselUniversity of Tübingen, Tübingen, Germany;

Kevin W. SongVancouver General Hospital, Vancouver, BC, Canada;

Craig J. GibsonCelgene Corporation, Summit, NJ, USA;

Owain SaundersBresMed Health Solutions, Sheffield, UK;

Lars Axel SternasCelgene Corporation, Summit, NJ, USA;

Kevin HongCelgene Corporation, Summit, NJ, USA;

Mohamed H. ZakiCelgene Corporation, Summit, NJ, USA;

Meletios A. DimopoulosAlexandra Hospital, Athens, Greece

show all

Figures & data

Table 1. Patient demographics in the POM + LoDEX arm at the start of C3Table Footnote*.

Download CSV Display Table

Figure 1. Response rates.

Figure 2. Responses achieved after 2 and 4 cycles of SD.

N.B. Patient numbers do not sum due to missing data points. C: cycle; D: day; PD: progressive disease; PR: partial response; SD: stable disease.

Figure 3. Landmark analysis. (A) POM + LoDEX arm; (B) Pooled POM + LoDEX and HiDEX arms.

Start of C7 analysis excludes patients with no data, or who were recorded as progressed/died prior to end of Cycle 2, 4, or 6, respectively. Performed with Kaplan-Meier method and unadjusted Cox regression model. HR: hazard ratio; OS: overall survival; PD: progressive disease; PR: partial response; SD: stable disease

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

Table 1. Patient demographics in the POM + LoDEX arm at the start of C3Table Footnote*.

Table 2. Grade ≥3 treatment-emergent adverse events (≥5%) on day 1 of C3.

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)

Figures & data

Table 1. Patient demographics in the POM + LoDEX arm at the start of C3Table Footnote*.

Table 2. Grade ≥3 treatment-emergent adverse events (≥5%) on day 1 of C3.

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date